Often on this blog I focus on challenges or problems in the stem cell universe, but sometimes it is important to focus on the good news and 2012 had much of that. There are more stem cell-based clinical trials than ever before and there is good reason to believe that many FDA-approved stem cell products […]
The good news about stem cells for 2012 Read More »
With stem cells there’s always all kinds of developments and news every week or even every day. Here is an assortment in no particular order of some of the latest news including some across the spectrum including weird and sometimes stuff. The linked phrases are often the actual headlines of the media pieces. New CIRM
Stem cell news update: the good, the bad, & the weird Read More »
In the whirlwind that is the stem cell and regenerative medicine world, there are many concerning things that need attention, but also good stuff happens too and this post focuses on the positive. The Asterias spinal cord injury clinical trial, a phase 1/2a trial called SCiStar, continues to make encouraging news with a clean safety profile
Good stem cell news on trials, FDA, cool new papers & more Read More »
Some good news today as the pioneering induced pluripotent stem (IPS) cell trial led by Dr. Masayo Takahashi will resume. This clinical study with a focus on macular degeneration has been on hold for quite some time due to regulatory changes in Japan. There had also been concerns over mutations in the 2nd patient’s IPS
Good stem cell news as Masayo Takahashi IPS Cell Trial to Resume Read More »
Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is expected to run from June 1 to June 10. Mesoblast will announce ““material corporate developments with respect to certain assets
Mesoblast stock on hold: Poll if you expect good or bad news Read More »
The FDA has been busy with the COVID pandemic but it has many other things on its plate as well including cell therapies. Today I’m sharing some recent agency news and brief perspectives on it. FDA focus on clinic-related umbilical cord cell drug makers The agency warned an Idaho company that produces and sells umbilical
FDA news: warning letter pattern, cancer moonshot, CAR-T & gene-editing guidance Read More »
I’d say the paper of the week is on how PRC2 mediated H3K27me3 can in some sense replace elements of DNA methylation to repress. Very cool. Here it is: Sex-specific chromatin remodelling safeguards transcription in germ cells, Nature. Weird stuff In a merger of opposites, City of Hope to buy Cancer Treatment Centers of America
Weekly reads: PRC2, 2 weird bits of news, pubs, COVID stem cell hype Read More »
How can you tell who to trust in the world of stem cell therapy? What information can a patient trust? Once upon a time about a dozen years ago it seemed a much simpler question. There were universities and biotech companies doing legit research as well as clinical trials, and there were physicians doing bone
Stem cell therapy: the good, the bad, & the muddy waters Read More »
It’s been a week with a wide variety of regenerative medicine papers and stem cell news. Here’s my earlier take from a few days ago on the Belmonte-led human-monkey chimeric embryo paper in Cell that broke this week. A few days ago I also put up a new video on our Stem Cell YouTube Channel
Even in COVID times the FDA continues its stepped-up efforts against stem cell clinics and patients are suing clinics more too, which I cover in today’s post along with recommended stem cell research pubs. One of the papers at the top of my to-read list is on 3D chromatin in stem cells. FDA Warning Letter
Weekly pubs & 2 stem cell clinics get bad news Read More »